Market research
CDXC Chromadex Corp
Former ticker of NAGE · through Mar 18, 2025
NASDAQ USD Consumer Defensive
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 199M
- P/E ratio
- 13.16
- Analyst target
- 12.0833
- Dividend yield
- Not available
- Beta
- 2.02
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- ISIN
- Not available
- Market cap
- 199M
- P/E ratio
- 13.16
- Analyst target
- 12.0833
- Dividend yield
- Not available
- Beta
- 2.02
About
About Chromadex Corp
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Research context
Chromadex Corp appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the CDXC discussion.
5 years, 6 months ago
ChromaDex Corporation is currently in a long term uptrend where the price is trading 25.5% above its 200 day moving average.
From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 11.3.
ChromaDex Corporation's total revenue rose by 18.0% to $15M since the same quarter in the previous year.
Its net income has increased by 31.1% to $-6M since the same quarter in the previous year.
Finally, its free cash flow grew by 85.4% to $-130K since the same quarter in the previous year.
Based on the above factors, ChromaDex Corporation gets an overall score of 5/5.